Italia markets closed

CureVac N.V. (0A9E.IL)

IOB - IOB Prezzo differito. Valuta in USD.
Aggiungi a watchlist
3,1525+0,1275 (+4,21%)
Alla chiusura: 06:40PM GMT

CureVac N.V.

Friedrich-Miescher-Strasse 15
Tübingen 72076
Germany
49 7071 9883 0
https://www.curevac.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno904

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Pierre Kemula B.Sc.MD, CFO & Member of Management Board582,02kN/D1975
Dr. Antony Blanc Ph.D.MD, Chief Bus. Officer, Chief Commercial Officer & Member of Management Board495,38kN/D1970
Dr. Malte Greune Ph.D.COO, Member of Management Board & MD452,64kN/D1965
Dr. Ulrike Gnad-Vogt M.D., Ph.D.Sr. VP & Area Head of Oncology371,63kN/D1973
Dr. Alexander Zehnder M.B.A., M.D.CEO, MD & Member of Management BoardN/DN/D1970
Dr. Myriam Mendila M.D.Chief Devel. Officer, MD & Member of the Management BoardN/DN/D1966
Dr. Sarah FakihVP Corp. Communications & Investor RelationsN/DN/DN/D
Mr. Marco Rau L.L.M., Ph.D.Gen. CounselN/DN/DN/D
Mr. Thorsten SchullerHead of Corp. CommunicationsN/DN/DN/D
Slavica Stevanovic-HeckHead of HRN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer therapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Governance aziendale

L'ISS Governance QualityScore di CureVac N.V. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.